You just read:

Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR™ In Vivo Gene Editing Technology

News provided by

Homology Medicines, Inc.

Aug 01, 2017, 07:00 ET